Browse the corpus

Walk the evidence base by book and chapter — the raw source passages that ground Ask, Differential, and the rest.

• "The Secret Life of Human Donor Hearts": An Examination of Transcriptomic Events During Cold Storage.1 passage
• (untitled)1 passage
• 2017 ACC/AHA/HFSA/ISHLT/ACP Advanced Training Statement on Advanced Heart Failure and Transplant Cardiology (Revision of the ACCF/AHA/ACP/HFSA/ISHLT 2010 Clinical Competence Statement on Management of Patients With Advanced Heart Failure and Cardiac Transplant): A Report of the ACC Competency Management Committee.1 passage
• A Novel Small Molecule Troponin Activator Increases Cardiac Contractile Function Without Negative Impact on Energetics.1 passage
• Abnormal Global Longitudinal Strain Predicts Future Deterioration of Left Ventricular Function in Heart Failure Patients With a Recovered Left Ventricular Ejection Fraction.1 passage
• Accelerometer-Measured Daily Activity in Heart Failure With Preserved Ejection Fraction: Clinical Correlates and Association With Standard Heart Failure Severity Indices.1 passage
• Accuracy and Usability of a Self-Administered 6-Minute Walk Test Smartphone Application.1 passage
• Accuracy of Seattle Heart Failure Model and HeartMate II Risk Score in Non-Inotrope-Dependent Advanced Heart Failure Patients: Insights From the ROADMAP Study (Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients).1 passage
• Activation of Autophagy Ameliorates Cardiomyopathy in1 passage
• Activities of daily living and outcomes in heart failure.1 passage
• Acute Dietary Nitrate Intake Improves Muscle Contractile Function in Patients With Heart Failure: A Double-Blind, Placebo-Controlled, Randomized Trial.1 passage
• Acute Hemodynamic Effects and Tolerability of Phosphodiesterase-1 Inhibition With ITI-214 in Human Systolic Heart Failure.1 passage
• Adenosine Kinase Inhibition Augments Conducted Vasodilation and Prevents Left Ventricle Diastolic Dysfunction in Heart Failure With Preserved Ejection Fraction.1 passage
• Adoption of Sacubitril/Valsartan for the Management of Patients With Heart Failure.1 passage
• Advanced Pulmonary and Cardiac Support of COVID-19 Patients: Emerging Recommendations From ASAIO1 passage
• Afro-Caribbean Heart Failure in the United Kingdom: Cause, Outcomes, and ATTR V122I Cardiac Amyloidosis.1 passage
• Age-related differences in phosphodiesterase activity and effects of chronic phosphodiesterase inhibition in idiopathic dilated cardiomyopathy.1 passage
• Alcohol and incident heart failure among middle-aged and elderly men: cohort of Swedish men.1 passage
• Altered Enhancer and Promoter Usage Leads to Differential Gene Expression in the Normal and Failed Human Heart.1 passage
• Angiogenic Imbalance and Residual Myocardial Injury in Recovered Peripartum Cardiomyopathy Patients.1 passage
• Antihyperglycemic Medication Use Among Medicare Beneficiaries With Heart Failure, Diabetes Mellitus, and Chronic Kidney Disease.1 passage
• Antiplatelet Therapy and Adverse Hematologic Events During Heart Mate II Support.1 passage
• Aortic Waveform Analysis to Individualize Treatment in Heart Failure.1 passage
• Approach to Acute Cardiovascular Complications in COVID-19 Infection.1 passage
• Aptamer-Based Proteomic Platform Identifies Novel Protein Predictors of Incident Heart Failure and Echocardiographic Traits.1 passage
• Assessment of Heterogeneity in Heart Failure-Related Meta-Analyses.1 passage
• Association Between Angiotensin Receptor-Neprilysin Inhibition, Cardiovascular Biomarkers, and Cardiac Remodeling in Heart Failure With Reduced Ejection Fraction.1 passage
• Association Between Coffee Intake and Incident Heart Failure Risk: A Machine Learning Analysis of the FHS, the ARIC Study, and the CHS.1 passage
• Association Between Poorer Cognitive Function and Reduced Objectively Monitored Medication Adherence in Patients With Heart Failure.1 passage
• Association Between Regional Adipose Tissue Distribution and Risk of Heart Failure Among Blacks.1 passage
• Association Between Use of Long-Acting Nitrates and Outcomes in Heart Failure With Preserved Ejection Fraction.1 passage
• Association Between Use of Statins and Mortality in Patients With Heart Failure and Ejection Fraction of ≥50.1 passage
• Association Between β-Blocker Use and Mortality/Morbidity in Patients With Heart Failure With Reduced, Midrange, and Preserved Ejection Fraction and Advanced Chronic Kidney Disease.1 passage
• Association between use of statins and outcomes in heart failure with reduced ejection fraction: prospective propensity score matched cohort study of 21 864 patients in the Swedish Heart Failure Registry.1 passage
• Association of Biomarker Clusters With Cardiac Phenotypes and Mortality in Patients With HIV Infection.1 passage
• Association of Concentric Left Ventricular Hypertrophy With Subsequent Change in Left Ventricular End-Diastolic Volume: The Dallas Heart Study.1 passage
• Association of Health Insurance Payer Type and Outcomes After Durable Left Ventricular Assist Device Implantation: An Analysis of the STS-INTERMACS Registry.1 passage
• Association of Hyper-Polypharmacy With Clinical Outcomes in Heart Failure With Preserved Ejection Fraction.1 passage
• Association of Physical Activity or Fitness With Incident Heart Failure: A Systematic Review and Meta-Analysis.1 passage
• Association of Sedentary Time and Incident Heart Failure Hospitalization in Postmenopausal Women.1 passage
• Association of Serum Erythropoietin With Cardiovascular Events, Kidney Function Decline, and Mortality: The Health Aging and Body Composition Study.1 passage
• Association of Weight and Body Composition on Cardiac Structure and Function in the ARIC Study (Atherosclerosis Risk in Communities).1 passage
• Association of the Novel Inflammatory Marker GlycA and Incident Heart Failure and Its Subtypes of Preserved and Reduced Ejection Fraction: The Multi-Ethnic Study of Atherosclerosis.1 passage
• Associations of Body Mass Index With Laboratory and Biomarkers in Patients With Acute Heart Failure.1 passage
• Automated E-Counseling for Chronic Heart Failure: CHF-CePPORT Trial.1 passage
• Avoidable Hospitalization for Heart Failure Among a Cohort of 18- to 64-Year-Old Italian Citizens and Immigrants: Results From the Italian Network for Longitudinal Metropolitan Studies.1 passage
• Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial.1 passage
• Baseline Characteristics of the VANISH Cohort.1 passage
• Baseline Hemodynamics and Response to Contrast Media During Diagnostic Cardiac Catheterization Predict Adverse Events in Heart Failure Patients.1 passage
• Baseline distribution of participants with depression and impaired quality of life in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial.1 passage
• Better Understanding the Disparity Associated With Black Race in Heart Transplant Outcomes: A National Registry Analysis.1 passage
• Biomarkers in Advanced Heart Failure: Implications for Managing Patients With Mechanical Circulatory Support and Cardiac Transplantation.1 passage
• Blood pressure and adverse events during continuous flow left ventricular assist device support.1 passage
• Body mass index and heart failure among patients with type 2 diabetes mellitus.1 passage
• Both high and low HbA1c predict incident heart failure in type 2 diabetes mellitus.1 passage
• Brain-Derived Neurotrophic Factor Improves Impaired Fatty Acid Oxidation Via the Activation of Adenosine Monophosphate-Activated Protein Kinase-ɑ - Proliferator-Activated Receptor-r Coactivator-1ɑ Signaling in Skeletal Muscle of Mice With Heart Failure.1 passage
• Bridging With Extracorporeal Membrane Oxygenation Under the New Heart Allocation System: A United Network for Organ Sharing Database Analysis.1 passage
• Burden of Systolic and Diastolic Left Ventricular Dysfunction Among Hispanics in the United States: Insights From the Echocardiographic Study of Latinos.1 passage
• Calcium/Calmodulin-Dependent Protein Kinase II Activity Persists During Chronic β-Adrenoceptor Blockade in Experimental and Human Heart Failure.1 passage
• Cancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 1: Definitions, Pathophysiology, Risk Factors, and Imaging.1 passage
• Cancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 2: Prevention, Treatment, Guidelines, and Future Directions.1 passage
• Cardiac Magnetic Resonance Imaging in Myocarditis Reveals Persistent Disease Activity Despite Normalization of Cardiac Enzymes and Inflammatory Parameters at 3-Month Follow-Up.1 passage
• Cardiac Microvascular Endothelial Cells in Pressure Overload-Induced Heart Disease.1 passage
• Cardiac Resynchronization Therapy and Risk of Recurrent Hospitalizations in Patients Without Left Bundle Branch Block: The Long-Term Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy.1 passage
• Cardiac Troponin I and Risk of Cardiac Events in Patients With Heart Failure and Preserved Ejection Fraction.1 passage
• Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan: Insights From a Combined PARAGON-HF and PARADIGM-HF Analysis.1 passage
• Cardiac structure and function across the glycemic spectrum in elderly men and women free of prevalent heart disease: the Atherosclerosis Risk In the Community study.1 passage
• Cardiometabolic Traits and Systolic Mechanics in the Community.1 passage
• Cardioprotective Effects of Sirtuin-1 and Its Downstream Effectors: Potential Role in Mediating the Heart Failure Benefits of SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors.1 passage
• Cardiopulmonary Exercise Testing and Prognosis in Hypertrophic Cardiomyopathy.1 passage
• Cardiorespiratory Fitness and Reclassification of Risk for Incidence of Heart Failure: The Veterans Exercise Testing Study.1 passage
• Cardiovascular Health Status and Incidence of Heart Failure in the Framingham Offspring Study.1 passage
• Care in the last year of life for community patients with heart failure.1 passage
• Carvedilol Compared With Metoprolol Succinate in the Treatment and Prognosis of Patients With Stable Chronic Heart Failure: Carvedilol or Metoprolol Evaluation Study.1 passage
• Causes and Predictors of 30-Day Readmission in Patients With Acute Myocardial Infarction and Cardiogenic Shock.1 passage
• Central cardiac limit to aerobic capacity in patients with exertional pulmonary venous hypertension: implications for heart failure with preserved ejection fraction.1 passage
• Changes in Aortic Wall Structure, Composition, and Stiffness With Continuous-Flow Left Ventricular Assist Devices: A Pilot Study.1 passage
• Changes in Dyspnea Status During Hospitalization and Postdischarge Health-Related Quality of Life in Patients Hospitalized for Heart Failure: Findings From the EVEREST Trial.1 passage
• Changing Demographics, Temporal Trends in Waitlist, and Posttransplant Outcomes After Heart Transplantation in the United States: Analysis of the UNOS Database 1991-2019.1 passage
• Characteristics and Healthcare Utilization Among Veterans Treated for Heart Failure With Reduced Ejection Fraction Who Switched to Sacubitril/Valsartan.1 passage
• Characteristics and Outcomes of COVID-19 in Patients on Left Ventricular Assist Device Support.1 passage
• Characteristics and Outcomes of Patients With Myocarditis Listed for Heart Transplantation.1 passage
• Characteristics and Outcomes of Women Developing Heart Failure After Early Stage Breast Cancer Chemotherapy: A Population-Based Matched Cohort Study.1 passage
• Characteristics and outcomes of patients with advanced chronic systolic heart failure receiving care at the Veterans Affairs versus other hospitals: insights from the Beta-blocker Evaluation of Survival Trial (BEST).1 passage
• Characteristics of Acute Heart Failure Hospitalizations Based on Presenting Severity.1 passage
• Characterizing Sex Differences in Physical Frailty Phenotypes in Heart Failure.1 passage
• Chronotropic Incompetence in Chronic Heart Failure.1 passage
• Clinical Characteristics and Outcomes of Adults With a History of Heart Failure Hospitalized for COVID-19.1 passage
• Clinical Characteristics and Outcomes of Intravenous Inotropic Therapy in Advanced Heart Failure.1 passage
• Clinical Characteristics and Outcomes of Patients With Coronary Artery Disease and Angina: Analysis of the Irbesartan in Patients With Heart Failure and Preserved Systolic Function Trial.1 passage
• Clinical Characteristics and Predictors of In-Hospital Mortality in Patients With Cardiogenic Shock: Results From the RESCUE Registry.1 passage
• Clinical Effectiveness of Hydralazine-Isosorbide Dinitrate Therapy in Patients With Heart Failure and Reduced Ejection Fraction: Findings From the Get With The Guidelines-Heart Failure Registry.1 passage
• Clinical Heart Failure Among Patients With and Without Severe Mental Illness and the Association With Long-Term Outcomes.1 passage
• Clinical Implications of Respiratory Failure in Patients Receiving Durable Left Ventricular Assist Devices for End-Stage Heart Failure.1 passage
• Clinical Outcomes Associated With Acute Mechanical Circulatory Support Utilization in Heart Failure Related Cardiogenic Shock.1 passage
• Clinical Outcomes and Quality of Life With an Ambulatory Counterpulsation Pump in Advanced Heart Failure Patients: Results of the Multicenter Feasibility Trial.1 passage
• Clinical Phenotype and Genotype Associations With Improvement in Left Ventricular Function in Dilated Cardiomyopathy.1 passage
• Clinical Phenotypes and Prognosis of Dilated Cardiomyopathy Caused by Truncating Variants in the1 passage
• Clinical Practice Patterns in Temporary Mechanical Circulatory Support for Shock in the Critical Care Cardiology Trials Network (CCCTN) Registry.1 passage
• Clinical Profile and Health Disparities in a Multiethnic Cohort of Patients With Hypertrophic Cardiomyopathy.1 passage
• Clinical Risk Stratification for Primary Prevention Implantable Cardioverter Defibrillators.1 passage
• Clinical Spectrum, Therapeutic Options, and Outcome of Advanced Heart Failure in Hypertrophic Cardiomyopathy.1 passage
• Clinical and Echocardiographic Outcomes After Bariatric Surgery in Obese Patients With Left Ventricular Systolic Dysfunction.1 passage
• Clinical and Genetic Investigations of 109 Index Patients With Dilated Cardiomyopathy and 445 of Their Relatives.1 passage
• Clinical and Hemodynamic Associations and Prognostic Implications of Ventilatory Efficiency in Patients With Preserved Left Ventricular Systolic Function.1 passage
• Clinical and In Vitro Evidence That Left Ventricular Assist Device-Induced von Willebrand Factor Degradation Alters Angiogenesis.1 passage
• Clinically Translatable Prevention of Anthracycline Cardiotoxicity by Dexrazoxane Is Mediated by Topoisomerase II Beta and Not Metal Chelation.1 passage
• Closing the Care Gap: A Primer on Quality Improvement for Heart Failure Clinicians.1 passage
• Cobalt Cardiomyopathy: A Critical Reappraisal in Light of a Recent Resurgence.1 passage
• Coenzyme Q10 and Heart Failure: A State-of-the-Art Review.1 passage
• Cognitive Domains and Postdischarge Outcomes in Hospitalized Patients With Heart Failure.1 passage
• Collaborative Regulation of LRG1 by TGF-β1 and PPAR-β/δ Modulates Chronic Pressure Overload-Induced Cardiac Fibrosis.1 passage
• Combining Diuretic Response and Hemoconcentration to Predict Rehospitalization After Admission for Acute Heart Failure.1 passage
• Comorbid Conditions and Health-Related Quality of Life in Ambulatory Heart Failure Patients: REVIVAL (Registry Evaluation of Vital Information for VADs in Ambulatory Life REVIVAL).1 passage
• Comparative Effectiveness of Cardiac Resynchronization Therapy Among Patients With Heart Failure and Atrial Fibrillation: Findings From the National Cardiovascular Data Registry's Implantable Cardioverter-Defibrillator Registry.1 passage
• Comparative Effectiveness of Implantable Cardioverter Defibrillators for Primary Prevention in Women.1 passage
• Comparative potential of the 2-item versus the 9-item patient health questionnaire to predict death or rehospitalization in heart failure.1 passage
• Comparing Sodium Intake Strategies in Heart Failure: Rationale and Design of the Prevent Adverse Outcomes in Heart Failure by Limiting Sodium (PROHIBIT) Study.1 passage
• Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction.1 passage
• Comparison of Outcome Adjudication by Investigators and by a Central End Point Committee in Heart Failure Trials: Experience of the SHIFT Heart Failure Study.1 passage
• Composite End Points in Clinical Trials of Heart Failure Therapy: How Do We Measure the Effect Size?1 passage
• Comprehensive Diagnostic Evaluation of Cardiovascular Physiology in Patients With Pulmonary Vascular Disease: Insights From the PVDOMICS Program.1 passage
• Comprehensive Hemodynamic Assessment in a Single Echocardiography Still Frame.1 passage
• Comprehensive Proteomics Profiling Reveals Circulating Biomarkers of Hypertrophic Cardiomyopathy.1 passage
• Conceptual Considerations for Device-Based Therapy in Acute Decompensated Heart Failure: DRI1 passage
• Contemporary Characteristics and Outcomes in Chagasic Heart Failure Compared With Other Nonischemic and Ischemic Cardiomyopathy.1 passage
• Contemporary Epidemiology of Heart Failure in Fee-For-Service Medicare Beneficiaries Across Healthcare Settings.1 passage
• Contemporary Management of Cardiogenic Shock: A RAND Appropriateness Panel Approach.1 passage
• Continuous Wearable Monitoring Analytics Predict Heart Failure Hospitalization: The LINK-HF Multicenter Study.1 passage
• Coronary Artery Remodeling and Fibrosis With Continuous-Flow Left Ventricular Assist Device Support.1 passage
• Correction to: Effect of Empagliflozin as an Add-On Therapy on Decongestion and Renal Function in Patients With Diabetes Hospitalized for Acute Decompensated Heart Failure: A Prospective Randomized Controlled Study.1 passage
• Current Limitations of Invasive Exercise Hemodynamics for the Diagnosis of Heart Failure With Preserved Ejection Fraction.1 passage
• Current Use of Hearts From Hepatitis C Viremic Donors.1 passage
• Cystatin C- Versus Creatinine-Based Assessment of Renal Function and Prediction of Early Outcomes Among Patients With a Left Ventricular Assist Device.1 passage
• Data-Driven Approach to Identify Subgroups of Heart Failure With Reduced Ejection Fraction Patients With Different Prognoses and Aldosterone Antagonist Response Patterns.1 passage
• Decoupling Between Diastolic Pulmonary Artery Pressure and Pulmonary Capillary Wedge Pressure as a Prognostic Factor After Continuous Flow Ventricular Assist Device Implantation.1 passage
• Decreased KCNE2 Expression Participates in the Development of Cardiac Hypertrophy by Regulation of Calcineurin-NFAT (Nuclear Factor of Activated T Cells) and Mitogen-Activated Protein Kinase Pathways.1 passage
• Defining Shock and Preshock for Mortality Risk Stratification in Cardiac Intensive Care Unit Patients.1 passage
• Defining a Clinically Important Change in 6-Minute Walk Distance in Patients With Heart Failure and Mitral Valve Disease.1 passage
• Definition of Iron Deficiency Based on the Gold Standard of Bone Marrow Iron Staining in Heart Failure Patients.1 passage
• Defying Dogma: Recovery After Left Ventricular Assist Device Implantation and Aortic Valve Replacement for Bicuspid Aortic Valve.1 passage
• Derivation and high engraftment of patient-specific cardiomyocyte sheet using induced pluripotent stem cells generated from adult cardiac fibroblast.1 passage
• Dermal Interstitial Alterations in Patients With Heart Failure and Reduced Ejection Fraction: A Potential Contributor to Fluid Accumulation?1 passage
• Design and Rationale of a Randomized Trial of a Care Transition Strategy in Patients With Acute Heart Failure Discharged From the Emergency Department: GUIDED-HF (Get With the Guidelines in Emergency Department Patients With Heart Failure).1 passage
• Design and Rationale of the Phase 3 ATTR-ACT Clinical Trial (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial).1 passage
• Determinants of Left Ventricular Diastolic Function and Exertional Symptoms in Adults With Coarctation of Aorta.1 passage
• Determinants of Survival in Older Adults With Congenital Heart Disease Newly Hospitalized for Heart Failure.1 passage
• Developing New Treatments for Heart Failure: Focus on the Heart.1 passage
• Development and Initial Validation of the PROMIS®-Plus-HF Profile Measure.1 passage
• Diagnosis and Treatment of Right Heart Failure in Pulmonary Vascular Diseases: A National Heart, Lung, and Blood Institute Workshop.1 passage
• Diastolic Pressure Difference to Classify Pulmonary Hypertension in the Assessment of Heart Transplant Candidates.1 passage
• Differences in Presentation and Outcomes Between Children With Familial Dilated Cardiomyopathy and Children With Idiopathic Dilated Cardiomyopathy: A Report From the Pediatric Cardiomyopathy Registry Study Group.1 passage
• Differential Cardiac MicroRNA Expression Predicts the Clinical Course in Human Enterovirus Cardiomyopathy.1 passage
• Differential Diagnosis of Mechanisms of Exercise-Induced Abnormal Blood Pressure Response in Hypertrophic Cardiomyopathy Without Left Ventricular Outflow Tract Obstruction.1 passage
• Differential Response to Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With Reduced or Preserved Ejection Fraction: Results From the ROSE AHF Trial (Renal Optimization Strategies Evaluation in Acute Heart Failure).1 passage
• Differential hemodynamic effects of exercise and volume expansion in people with and without heart failure.1 passage
• Digoxin Is Associated With a Decreased Incidence of Angiodysplasia-Related Gastrointestinal Bleeding in Patients With Continuous-Flow Left Ventricular Assist Devices.1 passage
• Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.1 passage
• Discharge Hospice Referral and Lower 30-Day All-Cause Readmission in Medicare Beneficiaries Hospitalized for Heart Failure.1 passage
• Disparity in the Setting of Incident Heart Failure Diagnosis.1 passage
• Diuretic Changes, Health Care Resource Utilization, and Clinical Outcomes for Heart Failure With Reduced Ejection Fraction: From the Change the Management of Patients With Heart Failure Registry.1 passage
• Donor Troponin and Survival After Cardiac Transplantation: An Analysis of the United Network of Organ Sharing Registry.1 passage
• Dose of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Outcomes in Heart Failure: A Meta-Analysis.1 passage
• Dose-Dependent Effects of the Myosin Activator Omecamtiv Mecarbil on Cross-Bridge Behavior and Force Generation in Failing Human Myocardium.1 passage
• Doxorubicin Exposure Causes Subacute Cardiac Atrophy Dependent on the Striated Muscle-Specific Ubiquitin Ligase MuRF1.1 passage
• Dual Endothelin-A/Endothelin-B Receptor Blockade and Cardiac Remodeling in Heart Failure With Preserved Ejection Fraction.1 passage
• Durable Mechanical Circulatory Support in Patients With Amyloid Cardiomyopathy: Insights From INTERMACS.1 passage
• Duration of Heart Failure Is an Important Predictor of Outcomes After Mechanical Circulatory Support.1 passage
• Duration of Heart Failure and Effect of Defibrillator Implantation in Patients With Nonischemic Systolic Heart Failure.1 passage
• Dying With a Left Ventricular Assist Device as Destination Therapy.1 passage
• Dynamic Changes in the Molecular Signature of Adverse Left Ventricular Remodeling in Patients With Compensated and Decompensated Chronic Primary Mitral Regurgitation.1 passage
• E/e' Ratio in Patients With Unexplained Dyspnea: Lack of Accuracy in Estimating Left Ventricular Filling Pressure.1 passage
• ERBB4 and Multiple MicroRNAs That Target ERBB4 Participate in Pregnancy-Related Cardiomyopathy.1 passage
• Early Ambulation Among Hospitalized Heart Failure Patients Is Associated With Reduced Length of Stay and 30-Day Readmissions.1 passage
• Early Escalation of Mechanical Circulatory Support Stabilizes and Potentially Rescues Patients in Refractory Cardiogenic Shock.1 passage
• Early Follow-Up After a Heart Failure Exacerbation: The Importance of Continuity.1 passage
• Early Preventive Treatment With Enalapril Improves Cardiac Function and Delays Mortality in Mice With Arrhythmogenic Right Ventricular Cardiomyopathy Type 5.1 passage
• Early Right Ventricular Assist Device Use in Patients Undergoing Continuous-Flow Left Ventricular Assist Device Implantation: Incidence and Risk Factors From the Interagency Registry for Mechanically Assisted Circulatory Support.1 passage
• Effect of Baseline Left Ventricular Ejection Fraction on 2-Year Outcomes After Transcatheter Aortic Valve Replacement: Analysis of the PARTNER 2 Trials.1 passage
• Effect of Blood Flow Restricted Resistance Exercise and Remote Ischemic Conditioning on Functional Capacity and Myocellular Adaptations in Patients With Heart Failure.1 passage
• Effect of Continuous-Flow Left Ventricular Assist Device Support on Coronary Artery Endothelial Function in Ischemic and Nonischemic Cardiomyopathy.1 passage
• Effect of Empagliflozin as an Add-On Therapy on Decongestion and Renal Function in Patients With Diabetes Hospitalized for Acute Decompensated Heart Failure: A Prospective Randomized Controlled Study.1 passage
• Effect of Empagliflozin on Blood Volume Redistribution in Patients With Chronic Heart Failure and Reduced Ejection Fraction: An Analysis from the Empire HF Randomized Clinical Trial.1 passage
• Effect of Everolimus Initiation and Calcineurin Inhibitor Elimination on Cardiac Allograft Vasculopathy in De Novo Heart Transplant Recipients.1 passage
• Effect of Inotropes on Patient-Reported Health Status in End-Stage Heart Failure: A Review of Published Clinical Trials.1 passage
• Effect of Intensive Blood Pressure Treatment on Heart Failure Events in the Systolic Blood Pressure Reduction Intervention Trial.1 passage
• Effect of estimated plasma volume reduction on renal function for acute heart failure differs between patients with preserved and reduced ejection fraction.1 passage
• Effective Arterial Elastance in the Pulmonary Arterial Circulation: Derivation, Assumptions, and Clinical Applications.1 passage
• Effects of Coping Skills Training on Quality of Life, Disease Biomarkers, and Clinical Outcomes in Patients With Heart Failure: A Randomized Clinical Trial.1 passage
• Effects of Liraglutide on Worsening Renal Function Among Patients With Heart Failure With Reduced Ejection Fraction: Insights From the FIGHT Trial.1 passage
• Effects of Omecamtiv Mecarbil on Symptoms and Health-Related Quality of Life in Patients With Chronic Heart Failure: Results From the COSMIC-HF Study.1 passage
• Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy.1 passage
• Effects of sildenafil on ventricular and vascular function in heart failure with preserved ejection fraction.1 passage
• Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial.1 passage
• Efficacy and Safety of Exercise Training in Chronic Pulmonary Hypertension: Systematic Review and Meta-Analysis.1 passage
• Efficacy and Safety of Sacubitril/Valsartan in High-Risk Patients in the PIONEER-HF Trial.1 passage
• Efficacy of Ranolazine in Patients With Symptomatic Hypertrophic Cardiomyopathy: The RESTYLE-HCM Randomized, Double-Blind, Placebo-Controlled Study.1 passage
• Elevated Angiotensin 1-7/Angiotensin II Ratio Predicts Favorable Outcomes in Patients With Heart Failure.1 passage
• Elevated Plasma Marinobufagenin, An Endogenous Cardiotonic Steroid, Is Associated With Right Ventricular Dysfunction and Nitrative Stress in Heart Failure.1 passage
• Elevated Soluble Fms-Like Tyrosine Kinase-1 and Placental-Like Growth Factor Levels Are Associated With Development and Mortality Risk in Heart Failure.1 passage
• Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure.1 passage
• Endothelial Leptin Receptor Deletion Promotes Cardiac Autophagy and Angiogenesis Following Pressure Overload by Suppressing Akt/mTOR Signaling.1 passage
• Endothelial Stromal PD-L1 (Programmed Death Ligand 1) Modulates CD81 passage
• Endothelial-Mesenchymal Transition in Heart Failure With a Preserved Ejection Fraction: Insights Into the Cardiorenal Syndrome.1 passage
• Enhanced Expression and Function of Renal SGLT2 (Sodium-Glucose Cotransporter 2) in Heart Failure: Role of Renal Nerves.1 passage
• Enhanced pulmonary vasodilator reserve and abnormal right ventricular: pulmonary artery coupling in heart failure with preserved ejection fraction.1 passage
• Epidemiology and Outcomes of Acute Decompensated Heart Failure in Children.1 passage
• Epidemiology of Cardiac Amyloidosis-Associated Heart Failure Hospitalizations Among Fee-for-Service Medicare Beneficiaries in the United States.1 passage
• Established and Emerging Roles of Biomarkers in Heart Failure Clinical Trials.1 passage
• Estimated Health Care Utilization and Expenditures in Individuals With Heart Failure From the Medical Expenditure Panel Survey.1 passage
• Evaluation of the Incremental Prognostic Utility of Increasingly Complex Testing in Chronic Heart Failure.1 passage
• Ex Vivo Assessment of Different Oral Anticoagulant Regimens on Pump Thrombosis in a HeartWare Ventricular Assist Device.1 passage
• Exception Status Listing in the New Adult Heart Allocation System: A New Solution to an Old Problem?1 passage
• Excess 30-Day Heart Failure Readmissions and Mortality in Black Patients Increases With Neighborhood Deprivation.1 passage
• Exercise Hemodynamic and Functional Capacity After Mitral Valve Replacement in Patients With Ischemic Mitral Regurgitation: A Comparison of Mechanical Versus Biological Prostheses.1 passage
• Exercise Ventricular Rates, Cardiopulmonary Exercise Performance, and Mortality in Patients With Heart Failure With Atrial Fibrillation.1 passage
• Exercise oscillatory ventilation in patients with Fontan physiology.1 passage
• Exercise training in patients with heart failure and preserved ejection fraction: meta-analysis of randomized control trials.1 passage
• Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis.1 passage
• Exploring New Endpoints for Patients With Heart Failure With Preserved Ejection Fraction.1 passage
• Expression and Implication of Clusterin in Left Ventricular Remodeling After Myocardial Infarction.1 passage
• Extracardiac Abnormalities of Preload Reserve: Mechanisms Underlying Exercise Limitation in Heart Failure with Preserved Ejection Fraction, Autonomic Dysfunction, and Liver Disease.1 passage
• Extracorporeal Membrane Oxygenation Use in Acute Myocardial Infarction in the United States, 2000 to 2014.1 passage
• Extracorporeal Membrane Oxygenation as a Bridge to Durable Mechanical Circulatory Support: An Analysis of the STS-INTERMACS Database.1 passage
• Extracorporeal Membrane Oxygenation as a Bridge to Pediatric Heart Transplantation: Effect on Post-Listing and Post-Transplantation Outcomes.1 passage
• Extracorporeal Membrane Oxygenation in New York State: Trends, Outcomes, and Implications for Patient Selection.1 passage
• FGF-23 (Fibroblast Growth Factor-23) and Cardiorenal Interactions.1 passage
• FGF21 (Fibroblast Growth Factor 21) Defines a Potential Cardiohepatic Signaling Circuit in End-Stage Heart Failure.1 passage
• Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial.1 passage
• Fatigability, Exercise Intolerance, and Abnormal Skeletal Muscle Energetics in Heart Failure.1 passage
• Fibroblast Growth Factor 23 Is an Independent and Specific Predictor of Mortality in Patients With Heart Failure and Reduced Ejection Fraction.1 passage
• First Successful Use of 2 Axial Flow Catheters for Percutaneous Biventricular Circulatory Support as a Bridge to a Durable Left Ventricular Assist Device.1 passage
• First-in-Human Experience With Transcatheter Mitral Valve-in-Valve Implantation During Left Ventricular Assist Device Placement.1 passage
• Floating Clots in the Descending Aorta: A Rare Complication of Femoral Venoarterial Extracorporeal Membrane Oxygenation Combined With Microaxial Pump for Cardiogenic Shock.1 passage
• Fluid Volume Overload and Congestion in Heart Failure: Time to Reconsider Pathophysiology and How Volume Is Assessed.1 passage
• Framework to Classify Reverse Cardiac Remodeling With Mechanical Circulatory Support: The Utah-Inova Stages.1 passage
• Frequency of Poor Outcome (Death or Poor Quality of Life) After Left Ventricular Assist Device for Destination Therapy: Results From the INTERMACS Registry.1 passage
• GNB3 C825T Polymorphism and Myocardial Recovery in Peripartum Cardiomyopathy: Results of the Multicenter Investigations of Pregnancy-Associated Cardiomyopathy Study.1 passage
• Global Differences in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial.1 passage
• Glycosylated Chromogranin A in Heart Failure: Implications for Processing and Cardiomyocyte Calcium Homeostasis.1 passage
• Goldilocks Dilemma of Dose Titration in Heart Failure With Reduced Ejection Fraction: Too Little, Too Much, or Just Right?1 passage
• HDACs Regulate miR-133a Expression in Pressure Overload-Induced Cardiac Fibrosis.1 passage
• Health Literacy Mediates the Relationship Between Age and Health Outcomes in Patients With Heart Failure.1 passage
• Health-Related Quality of Life Outcomes in PARADIGM-HF.1 passage
• Healthy Lifestyle and Risk of Heart Failure: Results From 2 Prospective Cohort Studies.1 passage
• Heart Failure Incidence and Mortality in the Southern Community Cohort Study.1 passage
• Heart Failure Increases the Risk of Adverse Renal Outcomes in Patients With Normal Kidney Function.1 passage
• Heart Failure Is Common and Under-Recognized in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia.1 passage
• Heart Failure With Improved Ejection Fraction: Clinical Characteristics, Correlates of Recovery, and Survival: Results From the Valsartan Heart Failure Trial.1 passage
• Heart Failure With Preserved Ejection Fraction Infrequently Evolves Toward a Reduced Phenotype in Long-Term Survivors.1 passage
• Heart Failure and Midrange Ejection Fraction: Implications of Recovered Ejection Fraction for Exercise Tolerance and Outcomes.1 passage
• Heart Failure and Shared Decision-Making: Patients Open to Medication-Related Cost Discussions.1 passage
• Heart Failure in Pregnant Women: A Concern Across the Pregnancy Continuum.1 passage
• Heart Transplantation With Donation After Circulatory Death.1 passage
• Heart Transplantation in Muscular Dystrophy Patients: Is it a Viable Option?1 passage
• HeartLogic Multisensor Algorithm Identifies Patients During Periods of Significantly Increased Risk of Heart Failure Events: Results From the MultiSENSE Study.1 passage
• Hemodynamic Effects of Mechanical Circulatory Support Devices in Ventricular Septal Defect.1 passage
• Hemodynamic Effects of Sacubitril-Valsartan Versus Enalapril in Patients With Heart Failure in the EVALUATE-HF Study: Effect Modification by Left Ventricular Ejection Fraction and Sex.1 passage
• Hemodynamic Phenotyping of Pulmonary Hypertension in Left Heart Failure.1 passage
• Hemodynamics of Fontan Failure: The Role of Pulmonary Vascular Disease.1 passage
• High-Intensity Interval Training Decreases Muscle Sympathetic Nerve Activity and Improves Peripheral Vascular Function in Patients With Heart Failure With Reduced Ejection Fraction.1 passage
• Histological and Histometric Characterization of Myocardial Fibrosis in End-Stage Hypertrophic Cardiomyopathy: A Clinical-Pathological Study of 30 Explanted Hearts.1 passage
• Home-Delivered Meals Postdischarge From Heart Failure Hospitalization.1 passage
• Hospice Enrollment in Patients With Advanced Heart Failure Decreases Acute Medical Service Utilization.1 passage
• How Big Is Too Big?: Donor Severe Obesity and Heart Transplant Outcomes.1 passage
• How Patients With Heart Failure Perform Daily Life Activities: An Innate Energy-Saving Strategy.1 passage
• Hypercapnia During Wakefulness Attenuates Ventricular Ectopy: Observations in a Young Man With Heart Failure With Reduced Ejection Fraction.1 passage
• Hypochloremia and Diuretic Resistance in Heart Failure: Mechanistic Insights.1 passage
• Hypochloremia, Diuretic Resistance, and Outcome in Patients With Acute Heart Failure.1 passage
• Hyporesponsiveness to Darbepoetin Alfa in Patients With Heart Failure and Anemia in the RED-HF Study (Reduction of Events by Darbepoetin Alfa in Heart Failure): Clinical and Prognostic Associations.1 passage
• IGFBP7 (Insulin-Like Growth Factor-Binding Protein-7) and Neprilysin Inhibition in Patients With Heart Failure.1 passage
• IL-1 Blockade in Patients With Heart Failure With Preserved Ejection Fraction.1 passage
• INDIE-HFpEF (Inorganic Nitrite Delivery to Improve Exercise Capacity in Heart Failure With Preserved Ejection Fraction): Rationale and Design.1 passage
• INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support) Profiling Identifies Ambulatory Patients at High Risk on Medical Therapy After Hospitalizations for Heart Failure.1 passage
• Ideal Cardiovascular Health, Cardiovascular Remodeling, and Heart Failure in Blacks: The Jackson Heart Study.1 passage
• Identification of Racial Inequities in Access to Specialized Inpatient Heart Failure Care at an Academic Medical Center.1 passage
• Identifying Discordance of Right- and Left-Ventricular Filling Pressures in Patients With Heart Failure by the Clinical Examination.1 passage
• Immunosuppressive Therapy Improves Both Short- and Long-Term Prognosis in Patients With Virus-Negative Nonfulminant Inflammatory Cardiomyopathy.1 passage
• Impact of Autonomic Regulation Therapy in Patients with Heart Failure: ANTHEM-HFrEF Pivotal Study Design.1 passage
• Impact of Baseline Hemodynamics on the Effects of a Transcatheter Interatrial Shunt Device in Heart Failure With Preserved Ejection Fraction.1 passage
• Impact of Diabetes Mellitus on Outcomes in Patients Supported With Left Ventricular Assist Devices: A Single Institutional 9-Year Experience.1 passage
• Impact of Hemodynamic Ramp Test-Guided HVAD Speed and Medication Adjustments on Clinical Outcomes.1 passage
• Impact of Incident Heart Failure on Body Composition Over Time in the Health, Aging, and Body Composition Study Population.1 passage
• Impact of Insulin Treatment on the Effect of Eplerenone: Insights From the EMPHASIS-HF Trial.1 passage
• Impact of Preeclampsia on Clinical and Functional Outcomes in Women With Peripartum Cardiomyopathy.1 passage
• Impact of Race on Clinical Outcomes After Implantation With a Fully Magnetically Levitated Left Ventricular Assist Device: An Analysis From the MOMENTUM 3 Trial.1 passage
• Impact of Socioeconomic Status on Patients Supported With a Left Ventricular Assist Device: An Analysis of the UNOS Database (United Network for Organ Sharing).1 passage
• Impact of Spironolactone on Longitudinal Changes in Health-Related Quality of Life in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial.1 passage
• Impact of Statin Use After Heart Transplantation: A Meta-Analysis.1 passage
• Impact of Ultrafiltration on Serum Sodium Homeostasis and its Clinical Implication in Patients With Acute Heart Failure, Congestion, and Worsening Renal Function.1 passage
• Impaired Protein Quality Control During Left Ventricular Remodeling in Mice With Cardiac Restricted Overexpression of Tumor Necrosis Factor.1 passage
• Impaired Right Ventricular-Pulmonary Arterial Coupling and Effect of Sildenafil in Heart Failure With Preserved Ejection Fraction: An Ancillary Analysis From the Phosphodiesterase-5 Inhibition to Improve Clinical Status And Exercise Capacity in Diastolic Heart Failure (RELAX) Trial.1 passage
• Impairments in Blood Pressure Regulation and Cardiac Baroreceptor Sensitivity Among Patients With Heart Failure Supported With Continuous-Flow Left Ventricular Assist Devices.1 passage
• Implantation of the HeartMate III Left Ventricular Assist Device in a Giant Left Ventricular Aneurysm: Is Left Ventricular Reconstruction Mandatory?1 passage
• Implications of Using Different Definitions on Outcomes in Worsening Heart Failure.1 passage
• Importance of Abnormal Chloride Homeostasis in Stable Chronic Heart Failure.1 passage
• Improvement in Left Ventricular Ejection Fraction in Outpatients With Heart Failure With Reduced Ejection Fraction: Data From CHAMP-HF.1 passage
• In Vitro and In Vivo Evaluation of a Small-Molecule APJ (Apelin Receptor) Agonist, BMS-986224, as a Potential Treatment for Heart Failure.1 passage
• Incidence and Outcomes of Acute Heart Failure With Preserved Versus Reduced Ejection Fraction in SPRINT.1 passage
• Incidence of New-Onset and Worsening Heart Failure Before and After the COVID-19 Epidemic Lockdown in Denmark: A Nationwide Cohort Study.1 passage
• Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril: The PARADIGM-HF Trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure).1 passage
• Incidence, Risk Factors, and Clinical Characteristics of Peripartum Cardiomyopathy in South Korea.1 passage
• Incident Atrial Fibrillation Is Associated With MYH7 Sarcomeric Gene Variation in Hypertrophic Cardiomyopathy.1 passage
• Increased Cardiac Uptake of Ketone Bodies and Free Fatty Acids in Human Heart Failure and Hypertrophic Left Ventricular Remodeling.1 passage
• Increased Risk of Congestive Heart Failure Following Carbon Monoxide Poisoning.1 passage
• Increased Thromboembolic Events With Dabigatran Compared With Vitamin K Antagonism in Left Ventricular Assist Device Patients: A Randomized Controlled Pilot Trial.1 passage
• Independent Prognostic Value of Serum Soluble ST2 Measurements in Patients With Heart Failure and a Reduced Ejection Fraction in the PARADIGM-HF Trial (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure).1 passage
• Induction Therapy With Antithymocyte Globulin in Patients Undergoing Cardiac Transplantation Is Associated With Decreased Coronary Plaque Progression as Assessed by Intravascular Ultrasound.1 passage
• Infection-Related Hospitalization in Heart Failure With Reduced Ejection Fraction: A Prospective Observational Cohort Study.1 passage
• Inflammation and Circulating Natriuretic Peptide Levels.1 passage
• Influence of Clinical Trial Site Enrollment on Patient Characteristics, Protocol Completion, and End Points: Insights From the ASCEND-HF Trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure).1 passage
• Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.1 passage
• Influence of Patient Goals of Care on Performance Measures in Patients Hospitalized for Heart Failure: An Analysis of the Enhanced Feedback For Effective Cardiac Treatment (EFFECT) Registry.1 passage
• Influence of Titration of Neurohormonal Antagonists and Blood Pressure Reduction on Renal Function and Decongestion in Decompensated Heart Failure.1 passage
• Inpatient Mortality Risk Scores and Postdischarge Events in Hospitalized Heart Failure Patients: A Community-Based Study.1 passage
• Insights Into Myocardial Oxygen Consumption, Energetics, and Efficiency Under Left Ventricular Assist Device Support Using Noninvasive Pressure-Volume Loops.1 passage
• Intake of Different Dietary Proteins and Risk of Heart Failure in Men: The Kuopio Ischaemic Heart Disease Risk Factor Study.1 passage
• Interleukin-1 Blockade in Recently Decompensated Systolic Heart Failure: Results From REDHART (Recently Decompensated Heart Failure Anakinra Response Trial).1 passage
• Internal Jugular Vein as Alternative Access for Implantation of a Wireless Pulmonary Artery Pressure Sensor.1 passage
• Intersection of Heart Failure and Pregnancy: Beyond Peripartum Cardiomyopathy.1 passage
• Intersection of Pulmonary Hypertension and Right Ventricular Dysfunction in Patients on Left Ventricular Assist Device Support: Is There a Role for Pulmonary Vasodilators?1 passage
• Intoxicated Donors and Heart Transplant Outcomes: Long-Term Safety.1 passage
• Intra-Aortic Balloon Pump Bridging to Heart Transplantation: Impact of the 2018 Allocation Change.1 passage
• Intra-Aortic Balloon Pumping in Acute Decompensated Heart Failure With Hypoperfusion: From Pathophysiology to Clinical Practice.1 passage
• Intra-aortic Balloon Pump As a Bridge to Heart Transplant After Non-ST-Segment-Elevation Myocardial Infarction in Palliated Hypoplastic Left Heart Syndrome.1 passage
• Intracardiac Pressures Measured Using an Implantable Hemodynamic Monitor: Relationship to Mortality in Patients With Chronic Heart Failure.1 passage
• Intravenous home inotropic use is safe in pediatric patients awaiting transplantation.1 passage
• Invasive Hemodynamic Assessment and Classification of In-Hospital Mortality Risk Among Patients With Cardiogenic Shock.1 passage
• Inverse Relationship of Blood Pressure to Long-Term Outcomes and Benefit of Cardiac Resynchronization Therapy in Patients With Mild Heart Failure: A Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy Long-Term Follow-Up Substudy.1 passage
• Is Myocarditis an Independent Risk Factor for Post-Transplant Mortality in Pediatric Heart Transplant Recipients?1 passage
• Is the Affordable Care Act Medicaid Expansion Linked to Change in Rate of Ventricular Assist Device Implantation for Blacks and Whites?1 passage
• Ivabradine in Heart Failure: The Representativeness of SHIFT (Systolic Heart Failure Treatment With the IF Inhibitor Ivabradine Trial) in a Broad Population of Patients With Chronic Heart Failure.1 passage
• Kansas City Cardiomyopathy Questionnaire Score Is Associated With Incident Heart Failure Hospitalization in Patients With Chronic Kidney Disease Without Previously Diagnosed Heart Failure: Chronic Renal Insufficiency Cohort Study.1 passage
• Kidney Disease Biomarkers Improve Heart Failure Risk Prediction in the General Population.1 passage
• Left Ventricular Assist Device Inflow Cannula Angle and Thrombosis Risk.1 passage
• Left Ventricular Mass Change After Anthracycline Chemotherapy.1 passage
• Left Ventricular Reverse Remodeling With Biventricular Versus Right Ventricular Pacing in Patients With Atrioventricular Block and Heart Failure in the BLOCK HF Trial.1 passage
• Left Ventricular T-Cell Recruitment Contributes to the Pathogenesis of Heart Failure.1 passage
• Left atrial remodeling and function in advanced heart failure with preserved or reduced ejection fraction.1 passage
• Letter by DeFilippis et al Regarding Article, "Sex Disparities in the Management and Outcomes of Cardiogenic Shock Complicating Acute Myocardial Infarction in the Young".1 passage
• Letter by Dell'Aquila et al Regarding Article, "Extracorporeal Membrane Oxygenation as a Bridge to Durable Mechanical Circulatory Support: an Analysis of the STS-INTERMACS Database".1 passage
• Letter by Gamble-George et al Regarding Article, "Identification of Racial Inequities in Access to Specialized Inpatient Heart Failure Care at an Academic Medical Center".1 passage
• Letter by Haddy Regarding Article, "Invasive and Echocardiographic Characteristics of a Patient With Severe Pulmonary Valve Regurgitation Pretending Severe Pulmonary Stenosis".1 passage
• Letter by Hardin and Araj Regarding Article, "Role of Pulmonary Artery Wedge Pressure Saturation During Right Heart Catheterization: A Prospective Study".1 passage
• Letter by Heinrich-Nols and Kreuzer Regarding Article, "Increased Thromboembolic Events With Dabigatran Compared With Vitamin K Antagonism in Left Ventricular Assist Device Patients: A Randomized Controlled Pilot Trial".1 passage
• Letter by Hutchings et al Regarding Article, "Preimplant Phosphodiesterase-5 Inhibitor Use Is Associated With Higher Rates of Severe Early Right Heart Failure After Left Ventricular Assist Device Implantation : An INTERMACS Analysis".1 passage
• Letter by Mareev et al Regarding Article, "Comparative Effectiveness of Implantable Cardioverter Defibrillators for Primary Prevention in Women".1 passage
• Letter by McAlister and Ezekowitz Regarding Article, "Temporal Trends and Variation in Early Scheduled Follow-Up After a Hospitalization for Heart Failure: Findings From Get With the Guidelines-Heart Failure".1 passage
• Letter by Mirwais et al Regarding Article, "Lower Rates of Heart Failure and All-Cause Hospitalizations During Pulmonary Artery Pressure-Guided Therapy for Ambulatory Heart Failure".1 passage
• Letter by Monneret et al Regarding Article, "Cardiac Structure and Function Across the Glycemic Spectrum in Elderly Men and Women Free of Prevalent Heart Disease: The Atherosclerosis Risk In the Community Study".1 passage
• Letter by Noeman et al Regarding Article "Prevalence of American Heart Association Heart Failure Stages in African-American and White Young and Middle-Aged Adults: The CARDIA Study".1 passage
• Letter by Tedford et al Regarding Article, "Effective Arterial Elastance in the Pulmonary Arterial Circulation: Derivation, Assumptions, and Clinical Applications".1 passage
• Levels of Trimethylamine N-Oxide Remain Elevated Long Term After Left Ventricular Assist Device and Heart Transplantation and Are Independent From Measures of Inflammation and Gut Dysbiosis.1 passage
• Liberation From Venoarterial Extracorporeal Membrane Oxygenation: A Review.1 passage
• Living Without a Pulse: The Vascular Implications of Continuous-Flow Left Ventricular Assist Devices.1 passage
• Load-Independent Systolic and Diastolic Right Ventricular Function in Heart Failure With Preserved Ejection Fraction as Assessed by Resting and Handgrip Exercise Pressure-Volume Loops.1 passage
• Long Noncoding RNA1 passage
• Long-Term Cognitive Decline After Newly Diagnosed Heart Failure: Longitudinal Analysis in the CHS (Cardiovascular Health Study).1 passage
• Long-Term Electrocardiographic and Echocardiographic Progression of Arrhythmogenic Right Ventricular Cardiomyopathy and Their Correlation With Ventricular Tachyarrhythmias.1 passage
• Long-Term Outcomes With Cardiac Resynchronization Therapy in Patients With Mild Heart Failure With Moderate Renal Dysfunction.1 passage
• Long-Term Survival After Heart Transplantation at Centers Stratified by Short-Term Performance.1 passage
• Long-Term Survival of Patients With Advanced Heart Failure Receiving an Left Ventricular Assist Device Intended as a Bridge to Transplantation: The Registry to Evaluate the HeartWare Left Ventricular Assist System.1 passage
• Long-Term Trajectories of Left Ventricular Ejection Fraction in Patients With Chronic Inflammatory Diseases and Heart Failure: An Analysis of Electronic Health Records.1 passage
• Longitudinal Assessment of Vascular Function With Sunitinib in Patients With Metastatic Renal Cell Carcinoma.1 passage
• Longitudinal Changes in Cardiac Structure and Function From Adolescence to Young Adulthood in Participants With Type 2 Diabetes Mellitus: The TODAY Follow-Up Study.1 passage
• Loss of secreted frizzled-related protein-1 leads to deterioration of cardiac function in mice and plays a role in human cardiomyopathy.1 passage
• Low Prevalence of Transcatheter Mitral Valve Repair Eligibility in a Community Heart Failure Population.1 passage
• Low- Versus Moderate-Sodium Diet in Patients With Recent Hospitalization for Heart Failure: The PROHIBIT (Prevent Adverse Outcomes in Heart Failure by Limiting Sodium) Pilot Study.1 passage
• Lower Rates of Heart Failure and All-Cause Hospitalizations During Pulmonary Artery Pressure-Guided Therapy for Ambulatory Heart Failure: One-Year Outcomes From the CardioMEMS Post-Approval Study.1 passage
• Management of Acute Myocarditis and Chronic Inflammatory Cardiomyopathy: An Expert Consensus Document.1 passage
• Marijuana and Listing for Heart Transplant: A Survey of Transplant Providers.1 passage
• Matching the Market for Heart Transplantation.1 passage
• Measured Versus Estimated Resting Metabolic Rate in Heart Failure With Preserved Ejection Fraction.1 passage
• Mechanical Circulatory Support Device Utilization and Heart Transplant Waitlist Outcomes in Patients With Restrictive and Hypertrophic Cardiomyopathy.1 passage
• Mechanism of Progressive Heart Failure and Significance of Pulmonary Hypertension in Obstructive Hypertrophic Cardiomyopathy.1 passage
• Mechanisms of Chronotropic Incompetence in Heart Failure With Preserved Ejection Fraction.1 passage
• Mechanisms of exercise intolerance in heart failure with preserved ejection fraction: the role of abnormal peripheral oxygen extraction.1 passage
• Mechanisms of the Multitasking Endothelial Protein NRG-1 as a Compensatory Factor During Chronic Heart Failure.1 passage
• Mechanistic Effects of Spironolactone on Cardiovascular and Renal Biomarkers in Heart Failure With Preserved Ejection Fraction: A TOPCAT Biorepository Study.1 passage
• Metabolically Healthy/Unhealthy Overweight/Obesity Associations With Incident Heart Failure in Postmenopausal Women: The Women's Health Initiative.1 passage
• Metabolomic Profiles and Heart Failure Risk in Black Adults: Insights From the Jackson Heart Study.1 passage
• MicroRNAs Associated With Reverse Left Ventricular Remodeling in Humans Identify Pathways of Heart Failure Progression.1 passage
• Microvascular Loss and Diastolic Dysfunction in Severe Symptomatic Cardiac Allograft Vasculopathy.1 passage
• Mini-cog performance: novel marker of post discharge risk among patients hospitalized for heart failure.1 passage
• Mitochondrial Morphology, Dynamics, and Function in Human Pressure Overload or Ischemic Heart Disease With Preserved or Reduced Ejection Fraction.1 passage
• Mode of Death in Patients With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF Trial.1 passage
• Mortality Among Patients Hospitalized With Heart Failure and Diabetes Mellitus: Results From the National Inpatient Sample 2000 to 2010.1 passage
• Mortality Associated With Heart Failure After Myocardial Infarction: A Contemporary Community Perspective.1 passage
• Multicenter Evaluation of Octreotide as Secondary Prophylaxis in Patients With Left Ventricular Assist Devices and Gastrointestinal Bleeding.1 passage
• Multidisciplinary Cardiac Rehabilitation and Long-Term Prognosis in Patients With Heart Failure.1 passage
• Multiparametric Implantable Cardioverter-Defibrillator Algorithm for Heart Failure Risk Stratification and Management: An Analysis in Clinical Practice.1 passage
• Multistate Model to Predict Heart Failure Hospitalizations and All-Cause Mortality in Outpatients With Heart Failure With Reduced Ejection Fraction: Model Derivation and External Validation.1 passage
• Myocardial Energetics in Heart Failure With Preserved Ejection Fraction.1 passage
• Myocardial Recovery in Patients Receiving Contemporary Left Ventricular Assist Devices: Results From the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS).1 passage
• Myocardial Tissue Reverse Remodeling After Guideline-Directed Medical Therapy in Idiopathic Dilated Cardiomyopathy.1 passage
• Myocardial Upregulation of Cathepsin D by Ischemic Heart Disease Promotes Autophagic Flux and Protects Against Cardiac Remodeling and Heart Failure.1 passage
• N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation Status.1 passage
• NOD2 (Nucleotide-Binding Oligomerization Domain 2) Is a Major Pathogenic Mediator of Coxsackievirus B3-Induced Myocarditis.1 passage
• National Burden of Heart Failure Events in the United States, 2006 to 2014.1 passage
• Neural Networks for Prognostication of Patients With Heart Failure.1 passage
• No Evidence of Myocardial Oxygen Deprivation in Nonischemic Heart Failure.1 passage
• Novel Approach Targeting the Complex Pathophysiology of Hypertrophic Cardiomyopathy: The Impact of Late Sodium Current Inhibition on Exercise Capacity in Subjects with Symptomatic Hypertrophic Cardiomyopathy (LIBERTY-HCM) Trial.1 passage
• Novel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of Elamipretide.1 passage
• Novel Model to Predict Gastrointestinal Bleeding During Left Ventricular Assist Device Support.1 passage
• Novel Trial Design: CHIEF-HF.1 passage
• Novel Wearable Seismocardiography and Machine Learning Algorithms Can Assess Clinical Status of Heart Failure Patients.1 passage
• Obese-Inflammatory Phenotypes in Heart Failure With Preserved Ejection Fraction.1 passage
• Obesity Predicts Survival After Cardiac Resynchronization Therapy Independent of Effect on Left Ventricular Ejection Fraction.1 passage
• Obesity and Outcomes Following Cardiogenic Shock Requiring Acute Mechanical Circulatory Support.1 passage
• Omega-3 Therapy Is Associated With Reduced Gastrointestinal Bleeding in Patients With Continuous-Flow Left Ventricular Assist Device.1 passage
• One-Year Outcomes After Transcatheter Insertion of an Interatrial Shunt Device for the Management of Heart Failure With Preserved Ejection Fraction.1 passage
• Optical Coherence Tomography in Cardiac Allograft Vasculopathy: State-of-the-Art Review.1 passage
• Optimal Hemodynamics During Left Ventricular Assist Device Support Are Associated With Reduced Readmission Rates.1 passage
• Optimal Strategy and Timing of Left Ventricular Venting During Veno-Arterial Extracorporeal Life Support for Adults in Cardiogenic Shock: A Systematic Review and Meta-Analysis.1 passage
• Oral Iron Therapy for Heart Failure With Reduced Ejection Fraction: Design and Rationale for Oral Iron Repletion Effects on Oxygen Uptake in Heart Failure.1 passage
• Outcomes After Continuous-Flow Left Ventricular Assist Device Implantation as Destination Therapy at Transplant Versus Nontransplant Centers.1 passage
• Outcomes in Patients With Hypertrophic Cardiomyopathy Awaiting Heart Transplantation.1 passage
• Participation in a Heart Failure Clinical Trial: Perspectives and Opportunities From the VICTORIA Trial and VICTORIA Simultaneous Registry.1 passage
• Pathogenic RBM20-Variants Are Associated With a Severe Disease Expression in Male Patients With Dilated Cardiomyopathy.1 passage
• Pathogenic Role of the Damage-Associated Molecular Patterns S100A8 and S100A9 in Coxsackievirus B3-Induced Myocarditis.1 passage
• Patient Characteristics, Clinical Outcomes, and Effect of Dapagliflozin in Relation to Duration of Heart Failure: Is It Ever Too Late to Start a New Therapy?1 passage
• Patient Perceptions on Facilitating Follow-Up After Heart Failure Hospitalization.1 passage
• Patient and Spousal Health and Outcomes in Heart Failure.1 passage
• Patient, Provider, and Practice Characteristics Associated With Sacubitril/Valsartan Use in the United States.1 passage
• Patient-Reported Health-Related Quality of Life Is a Predictor of Outcomes in Ambulatory Heart Failure Patients Treated With Left Ventricular Assist Device Compared With Medical Management: Results From the ROADMAP Study (Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management).1 passage
• Patient-Specific Computational Fluid Dynamics Reveal Localized Flow Patterns Predictive of Post-Left Ventricular Assist Device Aortic Incompetence.1 passage
• Pedal Edema as an Indicator of Early Heart Failure in the Community: Prevalence and Associations With Cardiac Structure/Function and Natriuretic Peptides (MESA [Multiethnic Study of Atherosclerosis]).1 passage
• Peripheral Venous Pressure Measurements in Patients With Acute Decompensated Heart Failure (PVP-HF).1 passage
• Peroxisome Proliferator Activated Receptor-α Association With Silent Information Regulator 1 Suppresses Cardiac Fatty Acid Metabolism in the Failing Heart.1 passage
• Pharmacological Silencing of MicroRNA-152 Prevents Pressure Overload-Induced Heart Failure.1 passage
• Phenotype and physiological significance of the endocardial smooth muscle cells in human failing hearts.1 passage
• Phosphodiesterase-5 Is Elevated in Failing Single Ventricle Myocardium and Affects Cardiomyocyte Remodeling In Vitro.1 passage
• Physical Function, Frailty, Cognition, Depression, and Quality of Life in Hospitalized Adults ≥60 Years With Acute Decompensated Heart Failure With Preserved Versus Reduced Ejection Fraction.1 passage
• Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction: Data From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction Study.1 passage
• Plasma Ceramides and Sphingomyelins in Relation to Heart Failure Risk.1 passage
• Plasma and Cardiac Galectin-3 in Patients With Heart Failure Reflects Both Inflammation and Fibrosis: Implications for Its Use as a Biomarker.1 passage
• Polygenic Score for β-Blocker Survival Benefit in European Ancestry Patients With Reduced Ejection Fraction Heart Failure.1 passage
• Polypharmacy in Older Adults Hospitalized for Heart Failure.1 passage
• Population risk prediction models for incident heart failure: a systematic review.1 passage
• Potential Role of Natriuretic Response to Furosemide Stress Test During Acute Heart Failure.1 passage
• Practice Patterns Surrounding Pregnancy After Heart Transplantation.1 passage
• Practice Patterns and Patient Outcomes After Widespread Adoption of Remote Heart Failure Care.1 passage
• Precision Medicine for Cardiac Resynchronization: Predicting Quality of Life Benefits for Individual Patients-An Analysis From 5 Clinical Trials.1 passage
• Preclinical Systolic and Diastolic Dysfunctions in Metabolically Healthy and Unhealthy Obese Individuals.1 passage
• Predicting Heart Failure With Preserved and Reduced Ejection Fraction: The International Collaboration on Heart Failure Subtypes.1 passage
• Predicting Risk in Patients Hospitalized for Acute Decompensated Heart Failure and Preserved Ejection Fraction: The Atherosclerosis Risk in Communities Study Heart Failure Community Surveillance.1 passage
• Predicting the Risk of Right Ventricular Failure in Patients Undergoing Left Ventricular Assist Device Implantation: A Systematic Review.1 passage
• Prediction of All-Cause Mortality Based on the Direct Measurement of Intrathoracic Impedance.1 passage
• Predictive Accuracy of Heart Failure-Specific Risk Equations in an Electronic Health Record-Based Cohort.1 passage
• Preimplant Phosphodiesterase-5 Inhibitor Use Is Associated With Higher Rates of Severe Early Right Heart Failure After Left Ventricular Assist Device Implantation.1 passage
• Preoperative Pectoralis Muscle Quantity and Attenuation by Computed Tomography Are Novel and Powerful Predictors of Mortality After Left Ventricular Assist Device Implantation.1 passage
• Preoperative Proteinuria and Reduced Glomerular Filtration Rate Predicts Renal Replacement Therapy in Patients Supported With Continuous-Flow Left Ventricular Assist Devices.1 passage
• Pressure-Volume Analysis Illustrating Left Ventricular Unloading by a Percutaneous Transvalvular Left Ventricular to Aortic Pump.1 passage
• Prevalence and Impact of Chagas Disease Among Latin American Immigrants With Nonischemic Cardiomyopathy in Los Angeles, California.1 passage
• Prevalence and Incidence of Heart Failure Among Urban Patients in China: A National Population-Based Analysis.1 passage
• Prevalence of American Heart Association Heart Failure Stages in Black and White Young and Middle-Aged Adults: The CARDIA Study.1 passage
• Prevalence of Pathogenic Gene Mutations and Prognosis Do Not Differ in Isolated Left Ventricular Dysfunction Compared With Dilated Cardiomyopathy.1 passage
• Pro-B-type natriuretic peptide-1-108 processing and degradation in human heart failure.1 passage
• Proenkephalin, an Opioid System Surrogate, as a Novel Comprehensive Renal Marker in Heart Failure.1 passage
• Progenitor Cells and Clinical Outcomes in Patients With Heart Failure.1 passage
• Prognostic Awareness and Goals of Care Discussions Among Patients With Advanced Heart Failure.1 passage
• Prognostic Importance of Changes in Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone.1 passage
• Prognostic Relevance of Left Atrial Dysfunction in Heart Failure With Preserved Ejection Fraction.1 passage
• Prognostic Role of Prior Heart Failure Hospitalization Among Patients Hospitalized for Worsening Chronic Heart Failure.1 passage
• Prognostic Significance of Creatinine Increases During an Acute Heart Failure Admission in Patients With and Without Residual Congestion: A Post Hoc Analysis of the PROTECT Data.1 passage
• Prognostic Significance of Resting Heart Rate and Use of β-Blockers in Atrial Fibrillation and Sinus Rhythm in Patients With Heart Failure and Reduced Ejection Fraction: Findings From the Swedish Heart Failure Registry.1 passage
• Prognostic Value of Albuminuria and Influence of Spironolactone in Heart Failure With Preserved Ejection Fraction.1 passage
• Prognostic Value of Dynamic Changes in Pulmonary Congestion During Exercise Stress Echocardiography in Heart Failure With Preserved Ejection Fraction.1 passage
• Prognostic Value of Elevated Levels of Plasma N-Acetylneuraminic Acid in Patients With Heart Failure.1 passage
• Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation.1 passage
• Prognostic Value of Secreted Frizzled-Related Protein 5 in Heart Failure Patients With and Without Type 2 Diabetes Mellitus.1 passage
• Prognostic significance of depression in blacks with heart failure: insights from Heart Failure: a Controlled Trial Investigating Outcomes of Exercise Training.1 passage
• Protein Aggregation Is an Early Manifestation of Phospholamban p.(Arg14del)-Related Cardiomyopathy: Development of PLN-R14del-Related Cardiomyopathy.1 passage
• Proteomic Bioprofiles and Mechanistic Pathways of Progression to Heart Failure.1 passage
• Proteomic Signatures During Treatment in Different Stages of Heart Failure.1 passage
• Proteomic and Functional Studies Reveal Detyrosinated Tubulin as Treatment Target in Sarcomere Mutation-Induced Hypertrophic Cardiomyopathy.1 passage
• Psychometric Evaluation of the Kansas City Cardiomyopathy Questionnaire in Men and Women With Heart Failure.1 passage
• Psychosocial Evaluation of Candidates for Heart Transplant and Ventricular Assist Devices: Beyond the Current Consensus.1 passage
• Psychosocial Factors and Risk of Incident Heart Failure: The Multi-Ethnic Study of Atherosclerosis.1 passage
• Psychosocial Factors, Exercise Adherence, and Outcomes in Heart Failure Patients: Insights From Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION).1 passage
• Psychosocial Risk and Its Association With Outcomes in Continuous-Flow Left Ventricular Assist Device Patients.1 passage
• Pulmonary Arterial Elastance and INTERMACS-Defined Right Heart Failure Following Left Ventricular Assist Device.1 passage
• Pulmonary Artery Pressure-Guided Heart Failure Management Reduces 30-Day Readmissions.1 passage
• Pulmonary Capillary Wedge Pressure Patterns During Exercise Predict Exercise Capacity and Incident Heart Failure.1 passage
• Pulmonary Effective Arterial Elastance as a Measure of Right Ventricular Afterload and Its Prognostic Value in Pulmonary Hypertension Due to Left Heart Disease.1 passage
• Pulmonary Hypertension Is Associated With a Higher Risk of Heart Failure Hospitalization and Mortality in Patients With Chronic Kidney Disease: The Jackson Heart Study.1 passage
• Pulmonary Production of Soluble ST2 in Heart Failure.1 passage
• Pulmonary Vascular Distensibility Predicts Pulmonary Hypertension Severity, Exercise Capacity, and Survival in Heart Failure.1 passage
• Quality of anticoagulation control in preventing adverse events in patients with heart failure in sinus rhythm: Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial substudy.1 passage
• Race- and Sex-Specific Population Attributable Fractions of Incident Heart Failure: A Population-Based Cohort Study From the Lifetime Risk Pooling Project.1 passage
• Racial Differences in Characteristics and Outcomes of Patients With Heart Failure and Preserved Ejection Fraction in the Treatment of Preserved Cardiac Function Heart Failure Trial.1 passage
• Racial Differences in Diuretic Efficiency, Plasma Renin, and Rehospitalization in Subjects With Acute Heart Failure.1 passage
• Racial and Ethnic Differences in Biomarkers, Health Status, and Cardiac Remodeling in Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan.1 passage
• Randomized Placebo-Controlled Trial of Ferric Carboxymaltose in Heart Failure With Iron Deficiency: Rationale and Design.1 passage
• Randomized pilot trial of gene expression profiling versus heart biopsy in the first year after heart transplant: early invasive monitoring attenuation through gene expression trial.1 passage
• Rapid and Highly Accurate Prediction of Poor Loop Diuretic Natriuretic Response in Patients With Heart Failure.1 passage
• Rationale and Design of the VITALITY-HFpEF Trial.1 passage
• Reassessing Phase II Heart Failure Clinical Trials: Consensus Recommendations.1 passage
• Recovery of Serum Cholesterol Predicts Survival After Left Ventricular Assist Device Implantation.1 passage
• Reduced Diuretic Dose in Patients Treated With Eplerenone: Data From the EPHESUS Trial.1 passage
• Reduced Myocardial Flow Reserve by Positron Emission Tomography Predicts Cardiovascular Events After Cardiac Transplantation.1 passage
• Reduced Myocardial Flow in Heart Failure Patients With Preserved Ejection Fraction.1 passage
• Reductions in N-Terminal Pro-Brain Natriuretic Peptide Levels Are Associated With Lower Mortality and Heart Failure Hospitalization Rates in Patients With Heart Failure With Mid-Range and Preserved Ejection Fraction.1 passage
• Referral Criteria to Palliative Care for Patients With Heart Failure: A Systematic Review.1 passage
• Regional Variation in RBM20 Causes a Highly Penetrant Arrhythmogenic Cardiomyopathy.1 passage
• Regional Variation in the Management and Outcomes of Acute Myocardial Infarction With Cardiogenic Shock in the United States.1 passage
• Regular wine consumption in chronic heart failure: impact on outcomes, quality of life, and circulating biomarkers.1 passage
• Relation of Magnesium Intake With Cardiac Function and Heart Failure Hospitalizations in Black Adults: The Jackson Heart Study.1 passage
• Relation of QRS Duration to Clinical Benefit of Cardiac Resynchronization Therapy in Mild Heart Failure Patients Without Left Bundle Branch Block: The Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy Substudy.1 passage
• Relationship Between Anticoagulation Intensity and Thrombotic or Bleeding Outcomes Among Outpatients With Continuous-Flow Left Ventricular Assist Devices.1 passage
• Relaxation and the Role of Calcium in Isolated Contracting Myocardium From Patients With Hypertensive Heart Disease and Heart Failure With Preserved Ejection Fraction.1 passage
• Relief and Recurrence of Congestion During and After Hospitalization for Acute Heart Failure: Insights From Diuretic Optimization Strategy Evaluation in Acute Decompensated Heart Failure (DOSE-AHF) and Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARESS-HF).1 passage
• Remodeling of the Purkinje Network in Congestive Heart Failure in the Rabbit.1 passage
• Remote Hemodynamic Monitoring Equally Reduces Heart Failure Hospitalizations in Women and Men in Clinical Practice: A Sex-Specific Analysis of the CardioMEMS Post-Approval Study.1 passage
• Renal Effects of Intensive Volume Removal in Heart Failure Patients With Preexisting Worsening Renal Function.1 passage
• Renal Sympathetic Denervation in Patients With Heart Failure With Preserved Ejection Fraction.1 passage
• Renin-Angiotensin System Inhibition, Worsening Renal Function, and Outcome in Heart Failure Patients With Reduced and Preserved Ejection Fraction: A Meta-Analysis of Published Study Data.1 passage
• Reporting of Lost to Follow-Up and Treatment Discontinuation in Pharmacotherapy and Device Trials in Chronic Heart Failure: A Systematic Review.1 passage
• Representation of Women Authors in International Heart Failure Guidelines and Contemporary Clinical Trials.1 passage
• Representativeness of the PIONEER-HF Clinical Trial Population in Patients Hospitalized With Heart Failure and Reduced Ejection Fraction.1 passage
• Reserve of Right Ventricular-Arterial Coupling in the Setting of Chronic Overload.1 passage
• Response by Andreas et al to Letter Regarding Article, "Increased Thromboembolic Events With Dabigatran Compared With Vitamin K Antagonism in Left Ventricular Assist Device Patients: A Randomized Controlled Pilot Trial".1 passage
• Response by Blanton et al to Letter Regarding Article, "Preimplant Phosphodiesterase-5 Inhibitor Use Is Associated With Higher Rates of Severe Early Right Heart Failure After LVAD Implantation: An INTERMACS Analysis".1 passage
• Response by Brener et al to Letter Regarding Article "Effective Arterial Elastance in the Pulmonary Arterial Circulation: Derivation, Assumptions, and Clinical Applications".1 passage
• Response by Eberly et al to Letter Regarding Article, "Identification of Racial Inequities in Access to Specialized Inpatient Heart Failure Care at an Academic Medical Center".1 passage
• Response by Loyaga-Rendon et al to Letter Regarding Article, "Extracorporeal Membrane Oxygenation as a Bridge to Durable Mechanical Circulatory Support: An Analysis of the STS INTERMACS Database".1 passage
• Response by Marquetand and Reil to Letter Regarding Article, "Invasive and Echocardiographic Characteristics of a Patient With Severe Pulmonary Valve Regurgitation Pretending Severe Pulmonary Stenosis".1 passage
• Response by Shavelle et al to Letters Regarding Article, "Lower Rates of Heart Failure and All-Cause Hospitalizations During Pulmonary Artery Pressure-Guided Therapy for Ambulatory Heart Failure: One-Year Outcomes From the CardioMEMS Post-Approval Study".1 passage
• Response by Vallabhajosyula to Letter Regarding Article, "Sex Disparities in the Management and Outcomes of Cardiogenic Shock Complicating Acute Myocardial Infarction in the Young".1 passage
• Response by Viray et al to Letter Regarding Article, "Role of Pulmonary Artery Wedge Pressure Saturation During Right Heart Catheterization: A Prospective Study".1 passage
• Response to Letter Regarding Article, "Temporal Trends and Variation in Early Scheduled Follow-up After a Hospitalization for Heart Failure: Findings from Get With The Guidelines-Heart Failure.1 passage
• Response to Letter Regarding Article, “Cardiac Structure and Function Across the Glycemic Spectrum in Elderly Men and Women Free of Prevalent Heart Disease: The Atherosclerosis Risk In the Community Study”.1 passage
• Right Heart Phenotype in Heart Failure With Preserved Ejection Fraction.1 passage
• Right Ventricular Function in Peripartum Cardiomyopathy at Presentation Is Associated With Subsequent Left Ventricular Recovery and Clinical Outcomes.1 passage
• Risk Factor Burden, Heart Failure, and Survival in Women of Different Ethnic Groups: Insights From the Women's Health Initiative.1 passage
• Risk Factors for Heart Failure: 20-Year Population-Based Trends by Sex, Socioeconomic Status, and Ethnicity.1 passage
• Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial.1 passage
• Risk of Heart Failure and Death After Prolonged Smoking Cessation: Role of Amount and Duration of Prior Smoking.1 passage
• Risk of heart failure among postmenopausal women: a secondary analysis of the randomized trial of vitamin D plus calcium of the women's health initiative.1 passage
• Risk-Based Approach for the Prediction and Prevention of Heart Failure.1 passage
• Safety of Endomyocardial Biopsy in New-Onset Acute Heart Failure Requiring Veno-Arterial Extracorporeal Membrane Oxygenation.1 passage
• Safety, Performance, and Efficacy of Cardiac Contractility Modulation Delivered by the 2-Lead Optimizer Smart System: The FIX-HF-5C2 Study.1 passage
• Sarcomeric Auto-Oscillations in Single Myofibrils From the Heart of Patients With Dilated Cardiomyopathy.1 passage
• Serum Chloride and Sodium Interplay in Patients With Acute Myocardial Infarction and Heart Failure With Reduced Ejection Fraction: An Analysis From the High-Risk Myocardial Infarction Database Initiative.1 passage
• Sex Differences at the Time of Myectomy in Hypertrophic Cardiomyopathy.1 passage
• Sex Differences in Mortality Based on United Network for Organ Sharing Status While Awaiting Heart Transplantation.1 passage
• Sex Differences in Quality of Life and Clinical Outcomes in Patients With Advanced Heart Failure: Insights From the PAL-HF Trial.1 passage
• Sex Disparities in the Management and Outcomes of Cardiogenic Shock Complicating Acute Myocardial Infarction in the Young.1 passage
• Sex-Based Differences in Left Ventricular Assist Device Utilization: Insights From the Nationwide Inpatient Sample 2004 to 2016.1 passage
• Sex-Related Differences in Heart Failure With Preserved Ejection Fraction.1 passage
• Sex-Specific Clinical Outcomes of the PACT-HF Randomized Trial.1 passage
• Shared Decision-Making About End-of-Life Care Scenarios Compared Among Implantable Cardioverter Defibrillator Patients: A National Cohort Study.1 passage
• Sharing the care of mechanical circulatory support: collaborative efforts of patients/caregivers, shared-care sites, and left ventricular assist device implanting centers.1 passage
• Short-Term Outcomes and Factors Associated With Adverse Events Among Adults Discharged From the Emergency Department After Treatment for Acute Heart Failure.1 passage
• Short-term intravenous sodium nitrite infusion improves cardiac and pulmonary hemodynamics in heart failure patients.1 passage
• Significance of Ischemic Heart Disease in Patients With Heart Failure and Preserved, Midrange, and Reduced Ejection Fraction: A Nationwide Cohort Study.1 passage
• Sildenafil Is Associated With Reduced Device Thrombosis and Ischemic Stroke Despite Low-Level Hemolysis on Heart Mate II Support.1 passage
• Skeletal Muscle Abnormalities and Iron Deficiency in Chronic Heart Failure1 passage
• Skeletal Muscle Function, Structure, and Metabolism in Patients With Heart Failure With Reduced Ejection Fraction and Heart Failure With Preserved Ejection Fraction.1 passage
• Sleep-Disordered Breathing Exacerbates Muscle Vasoconstriction and Sympathetic Neural Activation in Patients with Systolic Heart Failure.1 passage
• Small Endogeneous Peptide Mitigates Myocardial Remodeling in a Mouse Model of Cardioselective Galectin-3 Overexpression.1 passage
• Social Determinants of Health and 30-Day Readmissions Among Adults Hospitalized for Heart Failure in the REGARDS Study.1 passage
• Society of Thoracic Surgeons Risk Score and EuroSCORE-2 Appropriately Assess 30-Day Postoperative Mortality in the STICH Trial and a Contemporary Cohort of Patients With Left Ventricular Dysfunction Undergoing Surgical Revascularization.1 passage
• Socioeconomic Disparities in Adherence and Outcomes After Heart Transplant: A UNOS (United Network for Organ Sharing) Registry Analysis.1 passage
• Socioeconomic Disparities in Referral for Invasive Hemodynamic Evaluation for Advanced Heart Failure: A Nationwide Cohort Study.1 passage
• Standardized Psychosocial Assessment Before Left Ventricular Assist Device Implantation.1 passage
• Stem Cell and Left Ventricular Assist Device Combination Therapy.1 passage
• Stress and Coping Among Family Caregivers of Patients With a Destination Therapy Left Ventricular Assist Device: A Multicenter Mixed Methods Study.1 passage
• Study Design and Rationale of EXPLORER-HCM: Evaluation of Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy.1 passage
• Supplementation of l-Alanyl-l-Glutamine and Fish Oil Improves Body Composition and Quality of Life in Patients With Chronic Heart Failure.1 passage
• Survival Benefits of Invasive Versus Conservative Strategies in Heart Failure in Patients With Reduced Ejection Fraction and Coronary Artery Disease: A Meta-Analysis.1 passage
• Survival Outcomes After Heart Transplantation: Does Recipient Sex Matter?1 passage
• Survival and neurocognitive outcomes after cardiac extracorporeal life support in children less than 5 years of age: a ten-year cohort.1 passage
• Sympathoexcitation in Rats With Chronic Heart Failure Depends on Homeobox D10 and MicroRNA-7b Inhibiting GABBR1 Translation in Paraventricular Nucleus.1 passage
• Symptom Diary Use and Improved Survival for Patients With Heart Failure.1 passage
• Synergistic Impact of Systolic Blood Pressure and Perfusion Status on Mortality in Acute Heart Failure.1 passage
• TACIT (High Sensitivity Troponin T Rules Out Acute Cardiac Insufficiency Trial).1 passage
• TTR (Transthyretin) Stabilizers Are Associated With Improved Survival in Patients With TTR Cardiac Amyloidosis.1 passage
• Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes.1 passage
• Targeted DNA Methylation Profiling of Human Cardiac Tissue Reveals Novel Epigenetic Traits and Gene Deregulation Across Different Heart Failure Patient Subtypes.1 passage
• Temporal Trend of Age at Diagnosis in Hypertrophic Cardiomyopathy: An Analysis of the International Sarcomeric Human Cardiomyopathy Registry.1 passage
• Temporal Trends and Prognosis of Physical Examination Findings in Patients With Acute Decompensated Heart Failure: The ARIC Study Community Surveillance.1 passage
• Temporal Trends and Variation in Early Scheduled Follow-Up After a Hospitalization for Heart Failure: Findings from Get With The Guidelines-Heart Failure.1 passage
• Temporal Trends in Contemporary Use of Ventricular Assist Devices by Race and Ethnicity.1 passage
• Testing Medical Fairness: Incarceration and Eligibility for Advanced Heart Failure Therapies.1 passage
• Testing for Coronary Artery Disease in Older Patients With New-Onset Heart Failure: Findings From Get With The Guidelines-Heart Failure.1 passage
• The American Heart Association Heart Failure Summit, Bethesda, April 12, 2017.1 passage
• The Upcoming Epidemic of Heart Failure in South Asia.1 passage
• Thirty Years of Evidence on the Efficacy of Drug Treatments for Chronic Heart Failure With Reduced Ejection Fraction: A Network Meta-Analysis.1 passage
• Thirty-Day Readmissions After Left Ventricular Assist Device Implantation in the United States: Insights From the Nationwide Readmissions Database.1 passage
• Thyroid Dysfunction in Heart Failure and Cardiovascular Outcomes.1 passage
• Tolvaptan in Patients Hospitalized With Acute Heart Failure: Rationale and Design of the TACTICS and the SECRET of CHF Trials.1 passage
• Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure: Rationale and Design of the Randomized Trial to REDUCE Elevated Left Atrial Pressure in Heart Failure (REDUCE LAP-HF I).1 passage
• Transcatheter Mitral Valve Repair in Patients With and Without Cardiac Resynchronization Therapy: The COAPT Trial.1 passage
• Transcription Factor 7-like 2 Mediates Canonical Wnt/β-Catenin Signaling and c-Myc Upregulation in Heart Failure.1 passage
• Transcriptomic Analysis of Right Ventricular Remodeling in Two Rat Models of Pulmonary Hypertension: Identification and Validation of Epithelial-to-Mesenchymal Transition in Human Right Ventricular Failure.1 passage
• Transition of a Large Tertiary Heart Failure Program in Response to the COVID-19 Pandemic: Changes That Will Endure.1 passage
• Transitions of care in heart failure: a scientific statement from the American Heart Association.1 passage
• Transthyretin Cardiac Amyloidosis in Black Americans.1 passage
• Treatment Differences in Chronic Heart Failure Patients With Reduced Ejection Fraction According to Blood Pressure.1 passage
• Trends in 30- and 90-Day Readmission Rates for Heart Failure.1 passage
• Trends in 30-Day Readmission Rates for Patients Hospitalized With Heart Failure: Findings From the Get With The Guidelines-Heart Failure Registry.1 passage
• Trends in Left Ventricular Ejection Fraction for Patients With a New Diagnosis of Heart Failure.1 passage
• Trends in Noncardiovascular Comorbidities Among Patients Hospitalized for Heart Failure: Insights From the Get With The Guidelines-Heart Failure Registry.1 passage
• Trends in Place of Death for Cardiovascular Mortality Related to Heart Failure in the United States From 2003 to 2017.1 passage
• Trends in the Use of Inotropes to List Adult Heart Transplant Candidates at Status 1A.1 passage
• True Anemia-Red Blood Cell Volume Deficit-in Heart Failure: A Systematic Review.1 passage
• Two-Year Follow Up of the LATERAL Clinical Trial: A Focus on Adverse Events.1 passage
• Ultrasonic Assessment of Myocardial Microstructure in Hypertrophic Cardiomyopathy Sarcomere Mutation Carriers With and Without Left Ventricular Hypertrophy.1 passage
• Unbelievable Folly of Clinical Trials in Heart Failure: The Inconvenient Truth About How Investigators and Guidelines Weigh Evidence.1 passage
• Understanding Contemporary Use of Thiazolidinediones.1 passage
• Understanding the Complexity of Heart Failure Risk and Treatment in Black Patients.1 passage
• Use of Extracorporeal Membrane Oxygenation as Bridge to Replacement Therapies in Cardiogenic Shock: Insights From the Extracorporeal Life Support Organization.1 passage
• Use of Oral Anticoagulation in Eligible Patients Discharged With Heart Failure and Atrial Fibrillation.1 passage
• Use of Serum Transthyretin as a Prognostic Indicator and Predictor of Outcome in Cardiac Amyloid Disease Associated With Wild-Type Transthyretin.1 passage
• Use of β-Blockers in Pulmonary Hypertension.1 passage
• Utility of socioeconomic status in predicting 30-day outcomes after heart failure hospitalization.1 passage
• Utility of the Cardiovascular Physical Examination and Impact of Spironolactone in Heart Failure With Preserved Ejection Fraction.1 passage
• Validation and Comparison of Seven Mortality Prediction Models for Hospitalized Patients With Acute Decompensated Heart Failure.1 passage
• Validation of Cardiovascular Magnetic Resonance-Derived Equation for Predicted Left Ventricular Mass Using the UK Biobank Imaging Cohort: Tool for Donor-Recipient Size Matching.1 passage
• Validation of Noninvasive Measurement of Cardiac Output Using Inert Gas Rebreathing in a Cohort of Patients With Heart Failure and Reduced Ejection Fraction.1 passage
• Validity of Performance and Outcome Measures for Heart Failure.1 passage
• Variation in Hospital Use and Outcomes Associated With Pulmonary Artery Catheterization in Heart Failure in the United States.1 passage
• Venoarterial Extracorporeal Membrane Oxygenation for Cardiogenic Shock and Cardiac Arrest.1 passage
• Ventricular Assist Device Utilization in Heart Transplant Candidates: Nationwide Variability and Impact on Waitlist Outcomes.1 passage
• Ventricular conduction and long-term heart failure outcomes and mortality in African Americans: insights from the Jackson Heart Study.1 passage
• Ventricular square-wave response: case illustrating the role of invasive hemodynamics in the management of continuous-flow left ventricular assist device dysfunction.1 passage
• Virome Sequencing in Patients With Myocarditis.1 passage
• Von Willebrand factor improves risk prediction in addition to N-terminal pro-B-type natriuretic peptide in patients referred to coronary angiography and signs and symptoms of heart failure and preserved ejection fraction.1 passage
• Waiting Period Before Implantable Cardioverter-Defibrillator Implantation in Newly Diagnosed Heart Failure With Reduced Ejection Fraction: A Window of Opportunity.1 passage
• Watchful Waiting in Continuous-Flow Left Ventricular Assist Device Patients With Ongoing Hemolysis Is Associated With an Increased Risk for Cerebrovascular Accident or Death.1 passage
• What Number Are We?1 passage
• Who Should Deliver Medical Therapy for Patients With Chronic Heart Failure? An Immediate Call for Action to Implement a Community-Based Collaborative Solution.1 passage
• YKL-40 (Chitinase-3-Like Protein 1) Serum Levels in Aortic Stenosis.1 passage
• Yellow Wine Polyphenolic Compound Protects Against Doxorubicin-Induced Cardiotoxicity by Modulating the Composition and Metabolic Function of the Gut Microbiota.1 passage
• α-B Crystallin Reverses High Diastolic Stiffness of Failing Human Cardiomyocytes.1 passage
• β1 passage
• β-Blockers in Atrial Fibrillation Patients With or Without Heart Failure: Association With Mortality in a Nationwide Cohort Study.1 passage